Janssen (Johnson & Johnson) Deal History & Licensing Activity
Janssen (Johnson & Johnson) is a large pharma headquartered in US. Over the past three years, Janssen (Johnson & Johnson) has been involved in 13 licensing and acquisition transactions, with a primary focus on Small Molecules (10 deals). The company currently has 2 active clinical trials, primarily in Oncology.
Deals (12mo)
9
Active Trials
2
Top Modality
Small Molecules
Focus Area
Oncology
Janssen (Johnson & Johnson) Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Janssen (Johnson & Johnson) in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Dolasynthem ADC platform | Johnson & Johnson (Janssen) | ADC | Preclinical | collaboration | Aug 19, 2026 |
| Undisclosed | Johnson & Johnson | CAR-T | Preclinical | option | Jul 30, 2026 |
| Imbruvica | Janssen | Small Molecules | Approved | co development | Jul 20, 2026 |
| Imbruvica | AbbVie | Small Molecules | Approved | co development | Jul 18, 2026 |
| Imbruvica | Janssen | Small Molecules | Approved | co development | Jul 17, 2026 |
| LCB84 | Janssen | ADC | Unknown | license | Jun 14, 2026 |
| DAC oncology platform/pipeline | Johnson & Johnson | ADC | Preclinical | acquisition | Jun 8, 2026 |
| HLD-0915 / RIPTAC platform | Johnson & Johnson | Small Molecules | Unknown | acquisition | May 19, 2026 |
| JNJ-3989 / ARO-HBV | Arrowhead Pharmaceuticals | Oligonucleotides | Unknown | license | May 15, 2026 |
| JNJ-4804 | Royalty Pharma plc | Other | Unknown | co development | Mar 30, 2026 |
Showing 10 of 11 recent transactions. Upgrade to Pro for full deal history with financials.
Janssen (Johnson & Johnson) Pipeline Focus
Therapeutic areas and modalities where Janssen (Johnson & Johnson) is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Janssen (Johnson & Johnson) Strategic Signals
Key indicators of Janssen (Johnson & Johnson)'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Janssen (Johnson & Johnson) Clinical Pipeline
Janssen (Johnson & Johnson) has 2 active clinical trials across 2 development phases.
1
Not Applicable
1
Phase 4
See How Your Asset Matches Janssen (Johnson & Johnson)'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Oncology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Janssen (Johnson & Johnson) Licensing & Deal Activity
Janssen (Johnson & Johnson) is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 13 deals over the past three years, Janssen (Johnson & Johnson) ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Janssen (Johnson & Johnson) include Oncology (11 deals and trials), Codev Deals (6 deals and trials), Immunology (4 deals and trials), and Infectious Disease (2 deals and trials). In terms of modality, Janssen (Johnson & Johnson) has shown particular interest in small molecules, adc, car-t.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Janssen (Johnson & Johnson) and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Janssen (Johnson & Johnson)'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.